Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study.
Connor MJ, Genie M, Dudderidge T, Wu H, Sukumar J, Beresford M, Bianchini D, Goh C, Horan G, Innominato P, Khoo V, Klimowska-Nassar N, Madaan S, Mangar S, McCracken S, Ostler P, Paisey S, Robinson A, Rai B, Sarwar N, Srihari N, Jayaprakash KT, Varughese M, Winkler M, Ahmed HU, Watson V; IP5-MATTER Trial Investigators.
Connor MJ, et al. Among authors: wu h.
Eur Urol Oncol. 2024 Jul 6:S2588-9311(24)00158-5. doi: 10.1016/j.euo.2024.06.010. Online ahead of print.
Eur Urol Oncol. 2024.
PMID: 38972831
Free article.